Affordable Access

deepdyve-link
Publisher Website

A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors
  • Talaei, Ali1
  • Hosseini, Farhad Farid1
  • Aghili, Zahra2
  • Akhondzadeh, Shahin3
  • Asadpour, Elham4
  • Mehramiz, Neema John5
  • Forouzanfar, Fatemeh6, 7
  • 1 Psychiatry and Behavioral Sciences Research Center and Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , (Iran)
  • 2 Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. , (Iran)
  • 3 Psychiatric Research Center, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 4 Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. , (Iran)
  • 5 The University of Arizona, College of Medicine, Tucson, AZ 85724, USA.
  • 6 Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. , (Iran)
  • 7 Department of Neuroscience, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , (Iran)
Type
Published Article
Journal
Canadian Journal of Physiology and Pharmacology
Publisher
Canadian Science Publishing
Publication Date
Apr 01, 2020
Volume
98
Issue
4
Pages
236–242
Identifiers
DOI: 10.1139/cjpp-2019-0381
PMID: 32228235
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder, of unknown etiology, that affects 2.5% of the population. An appropriate therapeutic response to conventional treatment is seen. Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therapeutic response. In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments in patients with selective serotonin reuptake inhibitor (SSRI) refractory OCD. The OCD patients were initially treated for 12 weeks with a SSRI. If after 12 weeks their Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score was more than 16, they were randomly assigned to either the aripiprazole or the quetiapine augmentation group for an additional 12 weeks. There were no significant differences in age, sex, education, marital status, or score of Y-BOCS and Clinical Global Impression-Severity Scale (CGI-S) between groups (p > 0.05) at the outset of the study. Significant differences were noted after 1 month when compared with results at 2, 3, and 4 months in both groups (p < 0.001). Both quetiapine and aripiprazole may be effective and well-tolerated augmentative agents in the treatment of SSRI-refractory OCD. Because of positive results, aripiprazole may be considered more effective and may have a more rapid onset in terms of therapeutic response.

Report this publication

Statistics

Seen <100 times